Russian Federation: Human Rights

Debate between Wendy Morton and Layla Moran

Wednesday 27th January 2021 Commons Chamber

[Wendy Morton]

My hon. Friend raises a really important point. We have been very clear that the use of chemical weapons is an unacceptable breach of international norms. Russia absolutely must respond fully to the OPCW demand for a transparent investigation and, crucially, explain how a chemical weapon was used against a Russian citizen on Russian soil.

[Layla Moran (Oxford West and Abingdon) (LD) [V]]

Chelsea football club has been in the news a lot this week, though largely not for this issue. However, Alexei Navalny and his team released a list of names, drawn up by Navalny just days before his return and arrest, which included Chelsea FC’s owner Roman Abramovich and Everton FC’s Alisher Usmanov among those whom they believe should be sanctioned. Both individuals were described as

“key enablers…with significant ties and assets in the West.”

Is the Minister taking those allegations seriously? Will she provide an assurance that anyone, no matter their wealth or position, would be considered for Magnitsky sanctions?

[Wendy Morton]

As I have made clear in relation to Alexei Navalny, we enforced asset freezes and travel bans against six individuals and an entity involved with the poisoning and attempted murder of Mr Navalny on 15 October 2020. We did that under the EU’s chemical weapons sanctions regime. As the hon. Lady will recognise, try as she might to press me to speculate on further listings, alas I am not going to do that as it would be inappropriate.

Jonathan Taylor: SBM Offshore

Debate between Wendy Morton and Layla Moran

Monday 9th November 2020 Commons Chamber

[Wendy Morton]

The UK has seconded a senior lawyer to the Interpol taskforce, working to prevent the abuse of Interpol’s systems.

[Layla Moran (Oxford West and Abingdon) (LD)]

We owe a debt of gratitude to whistleblowers such as Mr Taylor, and corruption thrives at times of chaos, such as in a pandemic, for example. Transparency International has shown that there is a risk of global corruption rising as a result of this pandemic. Does the Minister not accept that this Government’s inaction sends the wrong signal to the very whistleblowers who we need on our side right now, and further to that, what are this Government doing to ensure that transparent processes are being followed during this pandemic?

[Wendy Morton]

What I do not accept is that this Government are not acting. I have repeatedly explained what we are doing in terms of support for Mr Taylor, particularly along the consular grounds, and I have made it very clear that we have no evidence that his arrest is linked to whistleblowing on corruption at SBM Offshore.

International Covid-19 Response: Innovation and Access to Treatment

Debate between Wendy Morton and Layla Moran

Thursday 5th November 2020 Commons Chamber

[Wendy Morton]

I will cover that point off later, if I may, but I make clear that we have made commitments to the ACT accelerator partners across the health technologies of up to £813 million. Our commitment is very clear. That includes up to £500 million to Gavi, the vaccine alliance, for the COVAX advance market commitment. The support will also help to ensure access to covid-19 vaccines for up to 92 low and middle-income countries, providing up to 500 million people with vaccinations. The UK is also the largest ACT accelerator donor to the Foundation for Innovative New Diagnostics, or FIND, which is leading the way in developing diagnostic tools for the world’s poorest countries.

In terms of treatments, the UK is providing up to £40 million to the covid-19 therapeutics accelerator, alongside the Bill and Melinda Gates Foundation, the Wellcome Trust, Mastercard and other funders. The covid-19 therapeutics accelerator and Unitaid lead the work of the ACT accelerator therapeutics partnership. Unitaid has a track record of helping companies to bring affordable health technologies to developing country markets quickly, and the UK is the second largest funder.

Our funding to the ACT accelerator is supporting a pipeline of promising treatments, including monoclonal antibodies and new antivirals. New clinical trial data will emerge in coming weeks. The ACT accelerator is also preparing the way for the rapid deployment of new therapeutics as soon as possible after they have proved effective. We have seen some impressive results so far, but we recognise that the scale of the crisis means more funding will be needed across all three health technologies. We will continue to work with our international partners to encourage them to join us in stepping up their support and to support new and innovative solutions to address this challenge.

The UK is proud to be at the forefront of international efforts to develop vaccines, treatments and tests and ensure equitable access for the world’s poorest countries, but we recognise that we cannot do that alone. Only through global collaboration with our international partners and working through effective multilateral systems will we bring the pandemic under control. That is why on 30 September, the Foreign Secretary co-hosted a side event at the UN General Assembly with the UN Secretary-General, the World Health Organisation director-general and the Health Minister of South Africa. The event raised up to $1 billion in bilateral contributions for the COVAX advance market commitment. The World Bank also announced a package of $12 billion of support for countries to access vaccines, treatments and tests, and a coalition of 16 industry leaders announced a shared commitment to equitable access, including not-for-profit pricing. The commitments by this range of partners are a powerful demonstration of the international support for the ACT accelerator and the need for partnership across the international system.

Vaccine nationalism was raised by Members on the Opposition Benches. In the UK, we are challenging vaccine nationalism. We are a leading supporter of the COVAX facility, which is open to all countries and aims to make vaccines widely available when they are proven. At the UN General Assembly, we used our diplomacy to convene countries in support of that and announced UK aid to fund the COVAX advance market commitment.

Intellectual property rights provide incentives to create and commercialise new inventions, such as life-changing vaccines. They keep innovators innovating, creators creating and investors investing. The UK believes that a robust and fair intellectual property system is a key part of the innovation framework that allows economies to grow while enabling society to benefit from knowledge and ideas. Multiple factors need to be considered to ensure equitable access for all to covid-19 vaccines. These include increasing manufacturing and distribution capacity, measures to support or incentivise technology transfer, ensuring that global supply chains remain open, and ensuring that effective platforms are utilised to voluntarily share IP and know-how.

The UK has long supported affordable and equitable access to essential medicines. We have not signed the solidarity call to action, but we remain committed to collaborating with public and private partners, including by exploring voluntary arrangements and approaches such as non-exclusive voluntary licensing.

[Layla Moran]

Will the Minister give way?

[Wendy Morton]

I would just like to make a bit more progress so that I can cover as many points as possible.

Several hon. Member asked about the allocation of vaccines. I assure them that this is being considered. The World Health Organisation’s allocation framework recommends the highest priority populations by age, underlying conditions and health workers—estimated at about 3%. We cannot prevent a country from administering doses as they want, but there is a framework and countries will submit national deployment plans that will be reviewed by the WHO and COVAX.

The hon. Member for Strangford (Jim Shannon) raised the issue of inequalities for minority groups. I assure all hon. Members that we are working closely with organisations such as UNICEF and Gavi in that regard. These are organisations that we have worked with for many years.

I really hope that the House is reassured by the Government’s comprehensive approach to supporting innovation and equitable access to covid-19 vaccines, through scientific co-operation, working with industry, funding and multilateral collaboration. The UK is leading efforts to respond to the pandemic by developing and delivering the medical tools that are essential to ending the pandemic for everyone everywhere, but we must all work together to develop safe, effective and affordable vaccines, treatments and tests that can be produced quickly and made available to all.